Abstract
Tuberculosis (TB) is the leading infectious disease cause of death worldwide. In recent years, stringent measures to contain the spread of SARS-CoV-2 have led to considerable disruptions of healthcare services for TB in many countries. The extent to which these measures have affected TB testing, treatment initiation and outcomes has not been comprehensively assessed. We aimed to estimate TB healthcare service disruptions occurring during the COVID-19 pandemic in Brazil, India, and South Africa. We obtained country-level TB programme and laboratory data and used autoregressive integrated moving average (ARIMA) time-series models to estimate healthcare service disruptions with respect to TB testing, treatment initiation, and treatment outcomes. We quantified disruptions as the percentage difference between TB indicator data observed during the COVID-19 pandemic compared with values for a hypothetical no-COVID scenario, predicted through forecasting of trends during a three-year pre-pandemic period. Annual estimates for 2020-2022 were derived from aggregated monthly data. We estimated that in 2020, the number of bacteriological tests conducted for TB diagnosis was 24.3% (95% uncertainty interval: 8.4%;36.6%) lower in Brazil, 27.8% (19.8;3 4.8%) lower in India, and 32.0% (28.9%;34.9%) lower in South Africa compared with values predicted for the no-COVID scenario. TB treatment initiations were 17.4% (13.9%;20.6%) lower than predicted in Brazil, 43.3% (39.8%;46.4%) in India, and 27.0% (15.2%;36.3%) in South Africa. Reductions in 2021 were less severe compared with 2020. The percentage deaths during TB treatment were 13.7% (8.1%; 19.7%) higher than predicted in Brazil, 1.7% (−8.9%;14.0%) in India and 21.8% (7.4%;39.2%) in South Africa. Our analysis suggests considerable disruptions of TB healthcare services occurred during the early phase of the COVID-19 pandemic in Brazil, India, and South Africa, with at least partial recovery in the following years. Sustained efforts to mitigate the detrimental impact of COVID-19 on TB healthcare services are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the following agencies, in the context of the BRICS STI Framework Programme: Brazilian Ministry of Science, Technology and Innovation, Conselho Nacional de Desenvolvimento e Pesquisa (CNPq- 441048/2020-0) Republic of South Africa, Department of Science and Innovation (DSI) and the South African Medical Research Council (SAMRC) under the BRICS JAF #2020/101. Department of Science and Technology, International Cooperation Division, Government of India (DST/INT/BRICS/Covid-19/2020-Part (2)). The content and findings of this article are the sole responsibility of the authors and do not necessarily reflect views and/or official positions of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was part of the IMPAC19TB project approved by the Ethics Committee of the Institute of Social Medicine, University of the State of Rio de Janeiro, Brazil (4.784.355), the Ethics Committee of the All India Institute of Medical Sciences in India (IEC-305/07.04.2021, RP-21/2021) and the Health Research Ethics Committee of Stellenbosch University, South Africa (N21/05/013_COVID-19) and local/national TB program approvals were obtained. All analyses for this study were based on aggregated (de-identified) programmatic and laboratory data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data on programmatic TB indicators used in this study were obtained from Departments of Health/National TB Programmes and country-level laboratory services, which are the custodians of the data. We are not permitted to publicly release these data on behalf of these institutions. We provide detailed information on data sources and availability in the manuscript. While enquiries to access the data must be made to the custodians, the authors of this study are willing, upon reasonable request to assist with contacting the respective institutions.
